Previous close | 218.15 |
Open | 219.63 |
Bid | 215.00 x 800 |
Ask | 230.35 x 900 |
Day's range | 216.72 - 221.40 |
52-week range | 132.24 - 237.26 |
Volume | |
Avg. volume | 1,120,314 |
Market cap | 31.876B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 33.33 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.92 (0.88%) |
Ex-dividend date | 08 May 2024 |
1y target est | N/A |
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.